Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Change in Interest Receivables (2021 - 2025)

Amylyx Pharmaceuticals (AMLX) has 5 years of Change in Interest Receivables data on record, last reported at -$6000.0 in Q4 2025.

  • For Q4 2025, Change in Interest Receivables rose 89.29% year-over-year to -$6000.0; the TTM value through Dec 2025 reached -$24000.0, up 93.31%, while the annual FY2025 figure was -$24000.0, 93.31% up from the prior year.
  • Change in Interest Receivables reached -$6000.0 in Q4 2025 per AMLX's latest filing, down from $55000.0 in the prior quarter.
  • Across five years, Change in Interest Receivables topped out at $609000.0 in Q2 2023 and bottomed at -$726000.0 in Q3 2023.
  • Average Change in Interest Receivables over 5 years is -$52411.8, with a median of -$6000.0 recorded in 2025.
  • The widest YoY moves for Change in Interest Receivables: up 4975.0% in 2023, down 25400.0% in 2023.
  • A 5-year view of Change in Interest Receivables shows it stood at $2000.0 in 2021, then tumbled by 27500.0% to -$548000.0 in 2022, then soared by 163.32% to $347000.0 in 2023, then plummeted by 116.14% to -$56000.0 in 2024, then soared by 89.29% to -$6000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Interest Receivables were -$6000.0 in Q4 2025, $55000.0 in Q3 2025, and -$7000.0 in Q2 2025.